AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$AUTL

Piccina Cintia sold $16K of AUTL

Piccina Cintia (U.S. CCO & Country Gen Manager) sold 6,713 shares of Autolus Therapeutics plc (AUTL) at $2.34 on 2026-09-02.

Original reporting
SEC EDGAR · Piccina Cintia
Published Sep 3, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUTL
Neutral
high confidence
Mentioned
$AUTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUTLNeutralLow
01

Why it matters

The transaction is a routine insider sale with minimal market effect.

02

Market read

Low relevance; the sale size is trivial and unlikely to move the stock.

03

What to watch

Potential upcoming clinical data could outweigh insider activity.

Relevance 3/10Novelty 5/10Timing: filing today

Background

Autolus Therapeutics plc is a biotech listed on Nasdaq (AUTL). The filing is a standard Form 4 disclosure.

Company-level read

Ticker impact

$AUTLNeutralHigh confidence
Context

Form 4 filing shows insider sold 6,713 shares for $15.7K, reducing holdings to 13,287 shares.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to market cap and no broader catalyst.

Market effects

Sector

None beyond the company.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

  • Officer
    Piccina Cintia

    U.S. Chief Commercial Officer & Country General Manager at Autolus.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUTL insider trading history →

Related articles

SEP 12
$AUTLMedAI 8/10

AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black

Autolus Therapeutics (AUTL) reported Q2 2026 revenue of $45.7M, up 119% YoY, driven by AUCATZYL sales. The company raised full-year guidance to $140M-$150M and secured a $250M credit facility. Despite improved margins, Autolus posted a $39.1M net loss and cash decreased to $201.6M. AUCATZYL carries significant safety warnings, and $150M of financing is tied to revenue milestones.

insidermonkey.com3 min
AUG 18
$AUTLMedAI 8/10

Autolus (AUTL) Q2 2026 Earnings Call Transcript

Autolus (AUTL) reported Q2 2026 net product revenue of $45.7M, up 119% YoY, and raised full-year guidance to $140M-$150M. Gross margin improved to 55%, and cash runway extends into Q2 2028. The company expanded treatment centers and saw initial U.K. sales.

fool.com6 min
AUG 11
$AUTLLow

Autolus Therapeutics plc (AUTL): Results of Operations and Financial Condition

Autolus Therapeutics plc (AUTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates August 11, 2026 at 7:00 AM EDT Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-year FY 2026 net prod

SEC EDGAR 8-K3 min